Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid ...

Harvest Portfolios Group Inc. is cooking up a new U.S. equity ETF. The Oakville, Ont.-based asset manager says it’s filed a ...

Wall Street is ending the week on a positive note, with stocks hitting fresh all-time highs amid a solid earnings season and ...

Hims & Hers (NYSE:HIMS) stock slips as U.S. lawmakers seek FDA action against copycat versions of weight loss drugs from Novo ...

Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease ...

European regulators on Friday said that the Duchenne muscular dystrophy gene therapy Elevidys should not be approved ...

Lupin Limited has received approval from the United States Food and Drug Administration for its Abbreviated New Drug ...

In recently reported case studies, nemolizumab, approved for two indications associated with itch, has been reported to be ...

Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...

Eli Lilly has cleared a major hurdle in its bid to win European approval for its Alzheimer's disease drug Kisunla.

Eli Lilly & Co. won the backing of European Union regulators for its Alzheimer’s disease drug Kisunla in a specific group of patients, potentially paving the way for it to become the second drug in ...

The data from 2019 to 2023 show rapid uptake of the drugs alongside wide patient- and practice-level variations.